Title

Field of Effects of Two Commercial Preparations of Botulinum Toxin Type A
Field Effects of Two Commercial Preparations of Botulinum Toxin Type a Administered to the Frontalis Muscles
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Intervention/Treatment

    rimabotulinumtoxinB ...
  • Study Participants

    29
The objective of this study is to compare the field of effects of the botulinum toxins (Dysport® and Botox®) using two equivalence-ratios and to gather supportive information, such as more detailed data on the effectiveness in reduction of wrinkles and duration of action on the upper part of the face of both products, trough scales and photographs evaluations.
This was a monocentric, prospective, randomized and double-blind study. Twenty nine female patients, presenting with moderate to severe forehead wrinkles, with sweating ability who had never undergone previous BoNT-A injections were enrolled. Subjects have received botulinum toxin type-A injections in two forehead sites, Botox 2U and Dysport 5U, both reconstituted in the same volume of 0.02 mL per point. Baseline, twenty-eight and 112 days later, clinical and photographic assessments, Minor´s test, and electromyographic (EMG) evaluations were performed.
Study Started
May 31
2005
Primary Completion
Nov 30
2007
Study Completion
Dec 31
2007
Results Posted
Apr 27
2010
Estimate
Last Update
Jun 02
2010
Estimate

Drug Botulinum Toxin Type A (Dysport®)

Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2,5:1. Both reconstituted in the same volume per point, injected in the forehead determined site. -Dysport®: 5 units will be injected in the left or right forehead side.

Drug Botulinum Toxin Type A/Botox®

2 units will be injected in the left or right forehead side.(opposite side of dysport injection)

Drug Botulinum Toxin Type A/Dysport®

Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site. -Dysport®: 4 units will be injected in the left or right forehead side, 2:1 ratio Dysport/Botox.

Botulinum toxin type - A Experimental

Dysport® compared to Botox®

Criteria

Inclusion Criteria:

Written Informed Consent (Annex 1)
Female
Subjects agreeing to take part in all procedures of the study, including botulinum toxin applications, Minor's test, measurement of Evoked Potentials, photographs, etc.), after being fully informed on the objectives and nature of the investigations
Subjects aged between 18 and 60 years
Subjects presenting with moderate to severe wrinkles on the forehead under maximum voluntary contraction of the m. frontalis

Subjects with positive Minor's test showing sweating on the forehead in standardized conditions described in Annex 2

*The Minor's Test will be the last inclusion criterion to be evaluated. Only these patients eligible according to the other inclusion criteria will undergo the Minor's Test to evaluate their sweating on the forehead. The cut off point is a positive Minor's Test (Level +1) - only subjects with Minor's Test (Level +1) will be recruited in the study (Annex 2).

Medical history and physical examination which, based on the investigator's opinion, do not prevent the patient from taking part in the study and use the products under investigation
Subjects of childbearing age should present a negative urine pregnancy test at baseline and should be using an effective contraceptive method;
Availability of the patient throughout the duration of the study (112 days)
Subject agrees not to undergo other cosmetic or dermatological procedures during the study
Subjects with sufficient schooling and awareness to enable them to cooperate to the degree required by this protocol

Exclusion Criteria:

Pregnant women or women intending to become pregnant in the next 4 months after screening for eligibility
Subjects who are lactating
Subjects having undergone botulinum toxin treatment within the last 6 months
Subjects participating in other clinical trials
Any prior surgery affecting the frontalis and/or orbicularis muscles, prior blepharoplasty or brow lift
Any prior cosmetic procedures, including fillers, or scars that may interfere with the study results
Subjects presenting fronto-parietal alopecia according to the Norwood-Hamilton classification
Subjects with neoplastic, muscular or neurological diseases
Subjects using aminoglycoside and penicillamine antibiotics, quinine and Ca2+ channel blockers
Subjects with inflammation or active infection in the area to be injected
Subjects presenting evident facial asymmetry
Subjects with a history of adverse effects, such as sensitivity to the components of the formula, ptosis or any other adverse effect, which in the investigator's opinion should prevent the patient from participating in the study
Subjects presenting myasthenia gravis, Eaton-Lambert Syndrome and motor neuron diseases
Subjects with coagulation disorders or using anticoagulants
Subjects with known systemic autoimmune diseases
Subjects with a history of medical treatment non-adherence or showing unwillingness to adhere to the study protocol
Any condition that, in the opinion of the investigator, can compromise the evaluation of the study

Summary

Dysport® 5U/ Botox® 2U

All Events

Event Type Organ System Event Term Dysport® 5U/ Botox® 2U

Horizontal Action Halo Diameter at 28 Days

The colorful complex formed by Minor's test allows the visualization of the area covered by the effects of botulinum toxin on sweat glands, also known as action halos. The horizontal diameter at day 28 were expressed in centimeters and quantified by the software Mirror® (Canfield Scientific Inc., USA).

Dysport® 5U

1.28
centimeter (Mean)
Standard Deviation: 0.26

Botox® 2U

1.12
centimeter (Mean)
Standard Deviation: 0.31

Horizontal Action Halo Diameter at 112 Days

The colorful complex formed by Minor's test allows the visualization of the area covered by the effects of botulinum toxin on sweat glands, also known as action halos. The horizontal diameter at day 112 were expressed in centimeters and quantified by the software Mirror® (Canfield Scientific Inc., USA).

Dysport® 5U

1.12
centimeter (Mean)
Standard Deviation: 0.26

Botox® 2U

0.96
centimeter (Mean)
Standard Deviation: 0.29

ECMAP in m. Frontialis

The measurement of the ECMAP(Evoked Compound Muscle Action Potentials) used surface electrodes on the forehead and electrical stimulation of the facial nerve, according to standard neurophysiological procedures. The amplitude of the ECMAP in the m. frontalis on stimulation of the facial nerve was performed by an experienced neurologist. ECMAP was assessed by an electromyography (EMG) device (TECA Sapphire - TECA Corp., Pleasantville, NY).

Dysport® 5U

492.53
microvolts (Mean)
Standard Deviation: 290.70

Botox ® 2U

468.27
microvolts (Mean)
Standard Deviation: 263.31

ECMAP in m. Frontialis

The measurement of the ECMAP(Evoked Compound Muscle Action Potentials) used surface electrodes on the forehead and electrical stimulation of the facial nerve, according to standard neurophysiological procedures. The amplitude of the ECMAP in the m. frontalis on stimulation of the facial nerve was performed by an experienced neurologist. ECMAP was assessed by an electromyography (EMG) device (TECA Sapphire - TECA Corp., Pleasantville, NY).

Dysport® 5U

482.63
microVolts (Mean)
Standard Deviation: 279.58

Botox® 2U

539.16
microVolts (Mean)
Standard Deviation: 387.72

Age, Categorical

Sex: Female, Male

Overall Study

Dysport® 5U/ Botox® 2U